Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

Kidney cancer

In crossover study, patients and physicians prefer pazopanib

Nature Reviews Urology volume 11, page 246 (2014)Cite this article

Subjects

The results of an innovative clinical trial have demonstrated significant preferences among both patients and physicians for pazopanib over sunitinib for treatment of metastatic renal cell carcinoma (mRCC).

A range of tyrosine kinase inhibitors is now approved for mRCC therapy, and the similar efficacies and safety profiles of these drugs means that alternative discriminatory factors are required. The similarities between pazopanib and sunitinib, both of which are approved by the FDA as first-line treatments, have now been exploited in the design of a crossover clinical trial.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Escudier, B. et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study. J. Clin. Oncol. 10.1200/JCO.2013.50.8267

Download references

Authors
  1. Robert Phillips
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Phillips, R. In crossover study, patients and physicians prefer pazopanib. Nat Rev Urol 11, 246 (2014). https://doi.org/10.1038/nrurol.2014.87

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrurol.2014.87

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing